Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

Launched by CENTRE ANTOINE LACASSAGNE · Feb 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking into special markers in the blood, known as biomarkers, that might help doctors predict how well a patient will respond to cancer treatments and how long they might live. By understanding these markers, researchers hope to improve cancer care and personalize treatment plans for patients.

The study is currently recruiting patients aged 65 to 74 who are having a blood test or an injection as part of their regular cancer treatment. To participate, patients need to be willing to allow their information to be used for research and must have social security coverage. Participants can expect to provide some blood samples, and their data will be kept confidential and used only for medical research. It's important to note that individuals who are already part of the study or are considered vulnerable may not be eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient having a blood test, venous line insertion or injection on an implantable venous device scheduled as part of their standard care,
• • Patient who has read the information note and stated that he/she has no objections
• • Patient who has not objected to the use of this data for medical research purposes
• • Patient with social security cover.
• Exclusion Criteria:
• • Patient already included in the study
• • Patient considered to be a vulnerable person; vulnerable persons are defined in article L1121-5 to -8